A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The division cycle of eukaryotic cells is regulated by a family of protein kinases known as the cyclin-dependent kinases (CDKs). The sequential activation of individual members of this family and their consequent phosphorylation of critical substrates promotes orderly progression through the cell cycle. The complexes formed by CDK4 and the D-type cyclins have been strongly implicated in the control of cell proliferation during the G1 phase. CDK4 exists, in part, as a multi-protein complex with a D-type cyclin, proliferating cell nuclear antigen and a protein, p21 (refs 7-9). CDK4 associates separately with a protein of M(r) 16K, particularly in cells lacking a functional retinoblastoma protein. Here we report the isolation of a human p16 complementary DNA and demonstrate that p16 binds to CDK4 and inhibits the catalytic activity of the CDK4/cyclin D enzymes. p16 seems to act in a regulatory feedback circuit with CDK4, D-type cyclins and retinoblastoma protein.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p16, on the other hand, acts through the Retinoblastoma (Rb) pathway (Serrano et al, 1993).”
From Distinct senotypes in p16- and p21-positive cells across human and mouse aging tissues (2025) · cites this paper as Serrano et al, 1993
In the citing paper
“p16INK4A is a 16 KDa protein that directly binds to CDK4/6 and blocks the formation of cyclinD-CDK4/6 complexes, thereby preventing phosphorylation of RB and promoting expression of E2F target genes (Serrano et al., 1993).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Serrano et al., 1993
In the citing paper
“This member of the INK4a family is a cyclin D-dependent kinase CDK4 and CDK6 inhibitor, which prevents the phosphorylation of the retinoblastoma protein (Rb), therefore leading to suspension of the cell cycle before the S-phase [78,79].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [78]
In the citing paper
“Currently, p16Ink4a is one of the widely used markers for studying cellular senescence, and it plays a prominent role in inhibiting CDK4/6 and restricting the progression of G1 to S phase in the cell cycle.16,17”
From Identifying specific functional roles for senescence across cell types (2024) · doi:10.1016/j.cell.2024.09.021 · cites this paper as [16]
In the citing paper
“Currently, p16Ink4a is one of the widely used markers for studying cellular senescence, and it plays a prominent role in inhibiting CDK4/6 and restricting the progression of G1 to S phase in the cell cycle.16,17”
From Identifying specific functional roles for senescence across cell types (2024) · doi:10.1016/j.cell.2024.09.021 · cites this paper as [16]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antibodies, a laboratory manual
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90130-3 · Cited by 12,366
A novel genetic system to detect protein–protein interactions
Fields, S., & Song, O.-K. (1989) · Nature · doi:10.1038/340245a0 · Cited by 6,114
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Self-citationSherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle
Matsushime, H., Roussel, M. F., Ashmun, R. A., & Sherr, C. J. (1991) · Cell · doi:10.1016/0092-8674(91)90101-4 · Cited by 1,167
Xiong, Y., Zhang, H., & Beach, D. (1992) · Cell · doi:10.1016/0092-8674(92)90518-h · Cited by 1,021
Self-citationFunctional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
A family of human cdc2-related protein kinases.
Meyerson, M., Enders, G. H., Wu, C. L., Su, L. K., Gorka, C., Nelson, C., Harlow, E., & Tsai, L. H. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05360.x · Cited by 923
Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897
Research works printed but not linked: 2
- Motokura, T. & Arnold, A. Biochim. biophys. Acta 1155, 63–78 (1993).
- Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. Oncogene (in the press).
Cited by
Items 101–200 of 1,022
Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence
Ohtani, N., Zebedee, Z., Huot, T. J. G., Stinson, J. A., Sugimoto, M., Ohashi, Y., Sharrocks, A. D., Peters, G., & Hara, E. (2001) · Nature · doi:10.1038/35059131 · Cited by 654
“jpg" NDATA ITEM> ]> The p16 INK4a cyclin-dependent kinase inhibito”
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA
Kaida, D., Motoyoshi, H., Tashiro, E., Nojima, T., Hagiwara, M., Ishigami, K., Watanabe, H., Kitahara, T., Yoshida, T., Nakajima, H., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.18 · Cited by 650
“On the other hand, p16, one of the INK4-family proteins, serves as a negative regulator for the D-type cyclin-dependent kinase”
BackgroundHirai, H., Roussel, M. F., Kato, J.-Y., Ashmun, R. A., & Sherr, C. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2672 · Cited by 646
“Induction of p16 in S phase might then act to extinguish CDK4 kinase activity after pRb undergoes phosphorylation, but in pRb-negative cells the protein would be expressed throughout the cell cycle (45).”
BackgroundInfluentialThe two-hybrid system: an assay for protein-protein interactions
Fields, S., & Sternglanz, R. (1994) · Trends in Genetics · doi:10.1016/0168-9525(90)90012-u · Cited by 646
(2002) · PubMed · Cited by 640
Inhibition of Cyclin‐Dependent Kinases by Purine Analogues
Veselý, J., Havliček, L., Strnad, M., Blow, J. J., Donella‐Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S., et al. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.00771.x · Cited by 632
Cellular senescence: a key therapeutic target in aging and diseases
Zhang, L., Pitcher, L. E., Yousefzadeh, M. J., Niedernhofer, L. J., Robbins, P. D., & Zhu, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158450 · Cited by 631
Chronic myeloid leukaemia as a model of disease evolution in human cancer
Melo, J. V., & Barnes, D. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2147 · Cited by 623
Increased Risk of Pancreatic Cancer in Melanoma-Prone Kindreds with p16INK4Mutations
Goldstein, A. M., Fraser, M. C., Struewing, J. P., Hussussian, C. J., Ranade, K., Zametkin, D. P., Fontaine, L. S., Organic, S. M., Dracopoli, N. C., Clark, W. H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510123331504 · Cited by 622
Structure–function of the multifunctional Ca2+/calmodulin-dependent protein kinase II
HUDMON, A., & SCHULMAN, H. (2002) · Biochemical Journal · doi:10.1042/bj20020228 · Cited by 615
Proliferative capacity of the corneal endothelium
Joyce, N. (2003) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(02)00065-4 · Cited by 611
E1A signaling to p53 involves the p19ARFtumor suppressor
de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S.-Y., Ferbeyre, G., Samuelson, A. V., Prives, C., Roussel, M. F., Sherr, C. J., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.15.2434 · Cited by 609
Divorcing ARF and p53: an unsettled case
Sherr, C. J. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1954 · Cited by 595
Human Cancer Syndromes: Clues to the Origin and Nature of Cancer
Fearon, E. R. (1997) · Science · doi:10.1126/science.278.5340.1043 · Cited by 605
Sano, T., Oyama, T., Kashiwabara, K., Fukuda, T., & Nakajima, T. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65689-1 · Cited by 579
“The CDKN2A gene product, p16 protein (p16), is a tumor suppressor protein that inhibits cyclin-dependent kinases (CDK)-4 and -6, which regulate the G1 checkpoint.(12,13) The CDKs phosphorylate pRb, which results in a conformational change and release of E2F from the pRb.”
BackgroundHigh frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma.
Reed, A. L., Califano, J. A., Cairns, P., Westra, W. H., Jones, R. M., Koch, W. M., Ahrendt, S. A., Eby, Y. J., Sewell, D. A., Nawroz, H., et al. (1996) · PubMed · Cited by 662
Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2
Gorina, S., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.1001 · Cited by 571
p16 INK4A is a robust in vivo biomarker of cellular aging in human skin
Ressler, S., Bartkova, J., Niederegger, H., Bartek, J., Scharffetter‐Kochanek, K., Jansen‐Dürr, P., & Wlaschek, M. (2006) · Aging Cell · doi:10.1111/j.1474-9726.2006.00231.x · Cited by 557
“…INK4a/ARF locus in humans encodes the functionally unrelated proteins p16INK4A and p14ARF that are both potent inhibitors of cell proliferation (Serrano et al., 1993) and act p16 as biomarker for skin aging, S. Ressler et al. © 2006 The Authors Journal compilation © Blackwell Publishing…”
BackgroundHolland, E. C., Hively, W. P., DePinho, R. A., & Varmus, H. E. (1998) · Genes & Development · doi:10.1101/gad.12.23.3675 · Cited by 556
UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer
de Gruijl, F. R., van Kranen, H. J., & Mullenders, L. H. F. (2001) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/s1011-1344(01)00199-3 · Cited by 544
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Mutations and altered expression of p16INK4 in human cancer.
Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., & Beach, D. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11045 · Cited by 539
Self-citationCyclins and cyclin-dependent kinases: a biochemical view
Pines, J. (1995) · Biochemical Journal · doi:10.1042/bj3080697 · Cited by 538
Russo, A. A., Tong, L., Lee, J.-O., Jeffrey, P. D., & Pavletich, N. P. (1998) · Nature · doi:10.1038/26155 · Cited by 524
“5 ); and the p16 INK4a tumour suppressor, which inhibits Cdk4/6”
BackgroundThe INK4A/ARF locus and its two gene products.
Sharpless, N. E., & DePinho, R. A. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80004-5 · Cited by 533
Relationship between Schistosomiasis and Bladder Cancer
Mostafa, M. H., Sheweita, S. A., & O’Connor, P. J. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.97 · Cited by 530
Carlson, B. A., Dubay, M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996) · PubMed · Cited by 580
Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia.
Cordon‐Cardo, C. (1995) · PubMed · Cited by 607
Shackelford, R. E., Kaufmann, W. K., & Paules, R. S. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00224-0 · Cited by 524
Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition
Koh, J., Enders, G. H., David Dynlacht, B., & Harlow, E. (1995) · Nature · doi:10.1038/375506a0 · Cited by 516
Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy
Choi, S., & Myers, J. N. (2008) · Journal of Dental Research · doi:10.1177/154405910808700104 · Cited by 516
“…in oral cancers (Heinzel et al., 1996). p16INK4a The p16 tumor suppressor gene maps to chromosome 9p21-22. p16 binds to the cyclin-dependent kinases CDK4 and CDK6 to inhibit cellular proliferation by preventing entry into the S phase of the cell cycle (Serrano et al., 1993; Kamb et al., 1994).”
BackgroundMalignant melanoma: genetics and therapeutics in the genomic era
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 511
“…(also known as p16INK4a)—the founding member of the INK4 (Inhibitor of cyclin-dependent kinase 4) family of proteins—inhibits the G1 cyclin-dependent kinases (CDKs) 4/6, which phosphorylate and inactivate the retinoblastoma protein (RB), thereby allowing for S-phase entry (Serrano et al. 1993).”
BackgroundGeographical Variation in the Penetrance of CDKN2A Mutations for Melanoma
Bishop, D. T. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.12.894 · Cited by 509
CDC25 Phosphatases as Potential Human Oncogenes
Galaktionov, K., Lee, A. K., Eckstein, J., Draetta, G., Meckler, J., Loda, M., & Beach, D. (1995) · Science · doi:10.1126/science.7667636 · Cited by 504
Self-citationMelanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496
“In concordance with these observations, some human melanomas have been known to amplify and/or mutate CDK4 (Muthusamy et al. 2006).”
InfluentialDe Azevedo, W. F., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., & Kim, S. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2735 · Cited by 496
(1995) · PubMed · Cited by 496
Hoffmann, I., Draetta, G., & Karsenti, E. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06750.x · Cited by 494
Gallo, R., Padurean, A., Jayaraman, T., Marx, S., Roque, M., Adelman, S., Chesebro, J., Fallon, J., Fuster, V., Marks, A., et al. (1999) · Circulation · doi:10.1161/01.cir.99.16.2164 · Cited by 490
Resistance to Apoptosis Conferred by Cdk Inhibitors During Myocyte Differentiation
Wang, J., & Walsh, K. (1996) · Science · doi:10.1126/science.273.5273.359 · Cited by 489
Inhibition of Myogenic Differentiation in Proliferating Myoblasts by Cyclin D1-Dependent Kinase
Skapek, S. X., Rhee, J., Spicer, D. B., & Lassar, A. B. (1995) · Science · doi:10.1126/science.7863328 · Cited by 477
MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis
Marjon, K., Cameron, M. J., Quang, P., Clasquin, M. F., Mandley, E., Kunii, K., McVay, M., Choe, S., Kernytsky, A., Gross, S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.043 · Cited by 485
Identification of CDK4 as a target of c-MYC
Hermeking, H., Rago, C., Schuhmacher, M., Li, Q., Barrett, J. F., Obaya, A. J., O'Connell, B. C., Mateyak, M. K., Tam, W., Kohlhuber, F., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050586197 · Cited by 471
p16(MTS-1/CDKN2/INK4a) in Cancer Progression
Rocco, J. W., & Sidransky, D. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5149 · Cited by 470
“Based on the biochemical and functional similarities between p16 and p15 (both enes encode proteins that bind and inactivate dk4–6/cyclin D complexes, resulting in G1 arrest [3]), deletions of both genes could provide a greater selective growth advantage than inactivation of either alone.”
BackgroundPancreatic cancer organoids recapitulate disease and allow personalized drug screening
Driehuis, E., van Hoeck, A., Moore, K., Kolders, S., Francies, H. E., Gulersonmez, M. C., Stigter, E. C. A., Burgering, B., Geurts, V., Gracanin, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911273116 · Cited by 459
Myc pathways provoking cell suicide and cancer
Nilsson, J. A., & Cleveland, J. L. (2003) · Oncogene · doi:10.1038/sj.onc.1207261 · Cited by 462
“…reading frame of the Ink4a locus (Quelle et al., 1995), which also encodes the p16 cyclin-dependent kinase (Cdk) inhibitor that inhibits D-type cyclin : Cdk4/Cdk6 complexes, which phosphorylate and inactivate the retinoblastoma (Rb) tumor suppressor (Serrano et al., 1993; Xiong et al., 1993).”
Backgroundp21 and p27: roles in carcinogenesis and drug resistance
Abukhdeir, A. M., & Park, B. H. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000744 · Cited by 463
pl9skp1 and p45skp2 are essential elements of the cyclin A-CDK2 S phase kinase
Zhang, H., Kobayashi, R., Galaktionov, K., & Beach, D. (1995) · Cell · doi:10.1016/0092-8674(95)90271-6 · Cited by 459
Self-citationAgeing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
“• p16INK4a: This member of the INK4a family is a cyclin D-dependent kinase CDK4 and CDK6 inhibitor, which prevents the phosphorylation of the retinoblastoma protein (Rb), therefore leading to suspension of the cell cycle before the S-phase [78,79].”
BackgroundGliomagenesis: genetic alterations and mouse models
Holland, E. C. (2001) · Nature Reviews Genetics · doi:10.1038/35052535 · Cited by 461
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., & Lowe, S. W. (1999) · Genes & Development · doi:10.1101/gad.13.20.2670 · Cited by 458
Zhu, X., Ohtsubo, M., Böhmer, R. M., Roberts, J. M., & Assoian, R. K. (1996) · The Journal of cell biology · doi:10.1083/jcb.133.2.391 · Cited by 453
INK4a/ARF: A multifunctional tumor suppressor locus
Sharpless, N. E. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.08.021 · Cited by 442
Joining the complex: Cyclin-dependent kinase inhibitory proteins and the cell cycle
Peter, M. (1994) · Cell · doi:10.1016/0092-8674(94)90186-4 · Cited by 445
Levkau, B., Koyama, H., Raines, E. W., Clurman, B. E., Herren, B., Orth, K., Roberts, J. M., & Ross, R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80055-6 · Cited by 441
Growth suppression by p16ink4 requires functional retinoblastoma protein
Medema, R. H., Herrera, R. E., Lam, F., & Weinberg, R. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6289 · Cited by 433
Mizuno, S.-I., Chijiwa, T., Okamura, T., Akashi, K., Fukumaki, Y., Niho, Y., & Sasaki, H. (2001) · Blood · doi:10.1182/blood.v97.5.1172 · Cited by 438
CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
Schmidt, E., Ichimura, K., Reifenberger, G., & Collins, V. P. (1994) · PubMed · Cited by 508
Aging Hallmarks and the Role of Oxidative Stress
Maldonado, E., Morales-Pison, S., Urbina, F., & Solari, A. (2023) · Antioxidants · doi:10.3390/antiox12030651 · Cited by 425
Cell-cycle inhibitors: three families united by a common cause
Vidal, A., & Koff, A. (2000) · Gene · doi:10.1016/s0378-1119(00)00092-5 · Cited by 431
Klussmann, J. P., Gültekin, E., Weissenborn, S. J., Wieland, U., Dries, V., Dienes, H. P., Eckel, H. E., Pfister, H. J., & Fuchs, P. G. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63871-0 · Cited by 431
Mendenhall, M. D., & Hodge, A. E. (1998) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.62.4.1191-1243.1998 · Cited by 429
Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease.
McShea, A., Harris, P. L. R., Webster, K. R., Wahl, A. F., & Smith, M. A. (1997) · Europe PMC (PubMed Central) · Cited by 467
Rates of p16 ( MTS1 ) Mutations in Primary Tumors with 9p Loss
Cairns, P., Mao, L., Merlo, A., Lee, D. J., Schwab, D., Eby, Y., Tokino, K., van der Riet, P., Blaugrund, J. E., & Sidransky, D. (1994) · Science · doi:10.1126/science.8023167 · Cited by 427
Goldstein, A. M., Chan, M., Harland, M., Gillanders, E. M., Hayward, N. K., Avril, M.-F., Azizi, E., Bianchi-Scarra, G., Bishop, D. T., Bressac-de Paillerets, B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0494 · Cited by 426
“The p16 protein regulates G1-phase exit by inhibiting the CDK4-mediated phosphorylation of the retinoblastoma protein (3, 4).”
BackgroundImplications of Genetic and Epigenetic Alterations of CDKN2A (p16 INK4a ) in Cancer
Zhao, R., Choi, B. Y., Lee, M.-H., Bode, A. M., & Dong, Z. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.017 · Cited by 425
“The p16INK4a protein is a protein consisting of 156 amino acids with a molecular weight of 16 kDa and is a negative regulator of the cell cycle (Serrano et al., 1993).”
BackgroundInfluentialVisone, R., Russo, L., Pallante, P., De Martino, I., Ferraro, A., Leone, V., Borbone, E., Petrocca, F., Alder, H., Croce, C. M., et al. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0129 · Cited by 417
“In fact, the Cip/Kip family together with INK4 proteins (p16INK4a, p15INK4b, p18INK4c, and p19INK4d), belongs to the cyclin-dependent kinase (CDK) inhibitors (Serrano et al. 1993, Guan et al. 1994, Hannon et al. 1994, Hirai et al. 1995).”
BackgroundMethodColeman, T. R., & Dunphy, W. G. (1994) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(94)90060-4 · Cited by 414
Dannenberg, J.-H., van Rossum, A., Schuijff, L., & te Riele, H. (2000) · Genes & Development · doi:10.1101/gad.847700 · Cited by 413
“Whereas p16INK4A was shown to act upstream of pRB to promote cell cycle arrest (Serrano et al. 1993), p19ARF can physically interact with p53 and/or MDM2, thereby antagonizing the function of MDM2 and stabilizing p53 (Kamijo et al. 1998; Pomerantz et al. 1998; Zhang et al. 1998).”
BackgroundSechi, S., & Chait, B. T. (1998) · Analytical Chemistry · doi:10.1021/ac9806005 · Cited by 407
Cell cycle and apoptosis: Common pathways to life and death
King, K. L., & Cidlowski, J. A. (1995) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240580206 · Cited by 406
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo
Chin, L., Pomerantz, J., Polsky, D., Jacobson, M., Cohen, C., Cordon-Cardo, C., Horner, J. W., & DePinho, R. A. (1997) · Genes & Development · doi:10.1101/gad.11.21.2822 · Cited by 402
“This region contains the closely linked INK4a and INK4b genes that encode the highly related G1 cyclin-dependent kinase inhibitors, p16Ink4a and p15Ink4b, respectively (Serrano et al. 1993; Hannon and Beach 1994; Kamb et al. 1994; Quelle et al. 1995a).”
BackgroundCdk inhibitors in development and cancer
Wade Harper, J., & Elledge, S. J. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)90011-8 · Cited by 399
Regulation of cyclin-Cdk activity in mammalian cells
Obaya, A. J., & Sedivy, J. M. (2002) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-002-8410-1 · Cited by 397
DNA Copy Number Losses in Human Neoplasms
Knuutila, S., Aalto, Y., Autio, K., Björkqvist, A.-M., El-Rifai, W., Hemmer, S., Huhta, T., Kettunen, E., Kiuru-Kuhlefelt, S., Larramendy, M. L., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65166-8 · Cited by 397
“Band 9p21 contains a tumor suppressor gene, CDKN2A (cyclin-dependent kinase inhibitor 2A), which encodes a cell-cycle inhibitor, p16.(59,60) Deletions at the locus often encompass and inactivate a gene nearby, CDKN2B (p15), which has similar functions as CDKN2A.”
BackgroundMolecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment
VanArsdale, T., Boshoff, C., Arndt, K. T., & Abraham, R. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0816 · Cited by 396
Differential gene expression during capillary morphogenesis in 3D collagen matrices
Bell, S. E., Mavila, A., Salazar, R., Bayless, K. J., Kanagala, S., Maxwell, S. A., & Davis, G. E. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.15.2755 · Cited by 395
Nakano, K., Mizuno, T., Sowa, Y., Orita, T., Yoshino, T., Okuyama, Y., Fujita, T., Ohtani-Fujita, N., Matsukawa, Y., Tokino, T., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.35.22199 · Cited by 395
Cell cycle checkpoints and their inactivation in human cancer
Molinari, M. (2000) · Cell Proliferation · doi:10.1046/j.1365-2184.2000.00191.x · Cited by 388
Soufir, N. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.2.209 · Cited by 386
“At the 9p21 locus the p16 gene (also called CDK4I, CDKN2 or MTS1) was identified as a gene encoding a protein of Mr 16 000 (p16INK4a) able to bind the cyclin-dependent kinase CDK4 ( 12 ).”
BackgroundActinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification
Röwert-Huber, J., Patel, M. J., Forschner, T., Ulrich, C., Eberle, J., Kerl, H., Sterry, W., & Stockfleth, E. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07860.x · Cited by 380
Cyclin D1 is an essential mediator of apoptotic neuronal cell death.
Kranenburg, O., van der Eb, A. J., & Zantema, A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00332.x · Cited by 379
Cyclin E-induced S phase without activation of the pRb/E2F pathway.
Lukas, J., Herzinger, T., Hansen, K., Moroni, M. C., Resnitzky, D., Helin, K., Reed, S. I., & Bartek, J. (1997) · Genes & Development · doi:10.1101/gad.11.11.1479 · Cited by 378
Inhibition of p21‐mediated ROS accumulation can rescue p21‐induced senescence
Macip, S., Igarashi, M., Fang, L., Chen, A., Pan, Z., Lee, S. W., & Aaronson, S. A. (2002) · The EMBO Journal · doi:10.1093/emboj/21.9.2180 · Cited by 374
Cellular and molecular events leading to the development of skin cancer
Melnikova, V. O., & Ananthaswamy, H. N. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.11.015 · Cited by 376
Chung, C. H., Zhang, Q., Kong, C. S., Harris, J., Fertig, E. J., Harari, P. M., Wang, D., Redmond, K. P., Shenouda, G., Trotti, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5228 · Cited by 374
“The p16 protein is an important tumor suppressor and cell-cycle regulator.(13) In HPV-positive tumors, the viral protein E7 binds to retinoblastoma susceptibility protein (Rb) through cullin 2 ubiquitin ligase complex and rapidly degrades Rb by ubiquitination.”
BackgroundInhibition of Ras-Induced Proliferation and Cellular Transformation by p16 INK4
Serrano, M., Gómez-Lahoz, E., DePinho, R. A., Beach, D., & Bar-Sagi, D. (1995) · Science · doi:10.1126/science.7809631 · Cited by 373
Self-citationSignaling Pathways that Control Cell Proliferation
Duronio, R. J., & Xiong, Y. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008904 · Cited by 372
“G1 M G2 S G0 DNA replication Cell division Cyclin-B–CDK1 Cyclin-E–CDK2 Cyclin-D–CDK4/6 R.J. Duronio and Y. Xiong 2 Cite this article as Cold Spring Harb Perspect Biol 2013;5:a008904 associated proteins and transcription factors, particularly members of the E2F family. pRB proteins negatively regulate the expression of…”
BackgroundInfluentialShort Dysfunctional Telomeres Impair Tumorigenesis in the INK4aΔ2/3 Cancer-Prone Mouse
Greenberg, R. A., Chin, L., Femino, A., Lee, K.-H., Gottlieb, G. J., Singer, R. H., Greider, C. W., & DePinho, R. A. (1999) · Cell · doi:10.1016/s0092-8674(00)80761-8 · Cited by 367
Jacobs, J. J. L., Keblusek, P., Robanus-Maandag, E., Kristel, P., Lingbeek, M., Nederlof, P. M., van Welsem, T., van de Vijver, M. J., Koh, E. Y., Daley, G. Q., et al. (2000) · Nature Genetics · doi:10.1038/81583 · Cited by 368
“A second control mechanism, which prevents cells from indefinite proliferation, is governed by the CDK inhibitor CDKN2A (also known as p16 INK4a ; ref”
BackgroundAbsence of WAF1 mutations in a variety of human malignancies
Shiohara, M., el-Deiry, W., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D., Vogelstein, B., & Koeffler, H. (1994) · Blood · doi:10.1182/blood.v84.11.3781.bloodjournal84113781 · Cited by 368
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Pandey, K., An, H., Kim, S. K., Lee, S. A., Kim, S., Lim, S. M., Kim, G. M., Sohn, J., & Moon, Y. W. (2019) · International Journal of Cancer · doi:10.1002/ijc.32020 · Cited by 361
“The p16, a member of INK4 family and a natural inhibitor of CDK4, is an important tumor suppressor involved in the regulation of cell cycle.(31) Naturally, p16 works as a tumor suppressor in the presence of functional RB because CDK4/6 (a target of p16) requires RB for its own kinase activity.”
BackgroundLukas, J., Bartkova, J., Rohde, M., Strauss, M., & Bartek, J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2600 · Cited by 366
“This result was unexpected since RB-deficient human cells examined so far showed very little if any evidence of cyclin D-cdk4 association, partly because of preferential complexing of cdk4 with the p16 kinase inhibitor (14, 54, 59).”
BackgroundInfluentialMelk, A., Schmidt, B. M. W., Takeuchi, O., Sawitzki, B., Rayner, D. C., & Halloran, P. F. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00438.x · Cited by 362
Cyclin D1: polymorphism, aberrant splicing and cancer risk
Knudsen, K. E., Diehl, J. A., Haiman, C. A., & Knudsen, E. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209371 · Cited by 363
“The concept that RB is a critical downstream target of cyclin D1 was reinforced by study of the p16ink4a tumor suppressor. p16ink4a binds directly to CDK4 and CDK6 and displaces cyclin D1 from the complex (Serrano et al., 1993; Koh et al., 1995; Russo et al., 1998; Jeffrey et al., 2000).”
BackgroundCell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site.
Schulze, A., Zerfass, K., Spitkovsky, D., Middendorp, S., Bergès, J., Helin, K., Jansen-Dürr, P., & Henglein, B. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.11264 · Cited by 361
Li, Y., Nichols, M. A., Shay, J. W., & Xiong, Y. (1994) · PubMed · Cited by 410
Khleif, S. N., DeGregori, J., Yee, C. L., Otterson, G. A., Kaye, F. J., Nevins, J. R., & Howley, P. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4350 · Cited by 358
Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein
Peeper, D. S., Upton, T. M., Ladha, M. H., Neuman, E., Zalvide, J., Bernards, R., DeCaprio, J. A., & Ewen, M. E. (1997) · Nature · doi:10.1038/386177a0 · Cited by 357
Parry, D., Bates, S., Mann, D. J., & Peters, G. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07026.x · Cited by 354
Metadata
- Authors
- Serrano, M., Hannon, G. J., & Beach, D.
- Affiliations
- Howard Hughes Medical Institute (US)
- ORCID
- Hannon, Gregory J.
- Venue
- Nature
- Published
- 1993-12
- Volume
- 366
- Issue
- 6456
- Pages
- 704-707
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2066848701
- Cited by
- 3,650
- References
- 22
- Citations by year
- 2026: 36 · 2025: 46 · 2024: 52 · 2023: 66 · 2022: 67 · 2021: 78 · 2020: 64 · 2019: 63 · 2018: 56 · 2017: 70 · 2016: 69 · 2015: 75 · 2014: 52 · 2013: 98 · 2012: 88
- FWCI
- 78.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p16, CDK4, cyclin D, cyclin-dependent kinases, cell cycle regulation, G1 phase, kinase inhibition, retinoblastoma protein, p21, proliferating cell nuclear antigen, feedback regulation, cell proliferation
- MeSH terms
- Amino Acid Sequence, Base Sequence, Carrier Proteins, Cell Cycle, Cloning, Molecular, DNA, Glutathione Transferase, HeLa Cells, Humans, Molecular Sequence Data, Phosphorylation, Proto-Oncogene Proteins, Recombinant Fusion Proteins, Saccharomyces cerevisiae, Oncogene Proteins, Retinoblastoma Protein, Cyclins, Cyclin-Dependent Kinases, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.